Prestige Consumer Healthcare Inc. — FY2020 Form 10-K
Period clarification: Although the request identifies “2019 Q4,” this filing reports the fiscal year ended March 31, 2020, with comparisons primarily to the fiscal year ended March 31, 2019. Amounts below are in U.S. dollars.
Business context and reporting period
Prestige develops, markets and distributes over-the-counter healthcare products. Its reportable segments are North American OTC Healthcare and International OTC Healthcare. The company sold its Household Cleaning segment in July 2018; FY2020 therefore includes no Household Cleaning revenue, while FY2019 includes a partial year. Walmart represented 23.1% of FY2020 gross revenue. The filing was signed May 8, 2020.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $963.0 million | $975.8 million |
| Gross profit / margin | $552.2 million / 57.3% | $555.6 million / 56.9% |
| Operating income | $291.2 million | $67.5 million |
| Net income (loss) | $142.3 million | ($35.8 million) |
| Diluted EPS | $2.78 | ($0.69) |
| Cash from operations | $217.1 million | $189.3 million |
| Capital expenditures | $14.6 million | $10.5 million |
| Cash and cash equivalents at year-end | $94.8 million | $27.5 million |
| Total debt, including current maturities | $1.745 billion | $1.813 billion |
FY2020 operating margin was approximately 30.2% and net margin approximately 14.8%; the prior-year figures were materially affected by impairment charges. Current assets were $365.7 million and current liabilities $149.9 million at March 31, 2020. The company reported $107.3 million of remaining ABL borrowing capacity and said operating cash flows and credit facilities were expected to cover working capital and capital expenditures over the next 12 months, excluding acquisitions.
Material changes versus the prior comparable period
- Consolidated revenue declined 1.3%, mainly because FY2019 included Household Cleaning revenue after the July 2018 divestiture. OTC Healthcare revenue increased 0.7% overall: North American revenue fell 0.4%, while International revenue rose 10.8%.
- North American OTC gross margin declined to 56.7% from 57.7%, primarily due to costs of changing warehouse locations. International OTC gross margin improved to 62.7% from 58.2%, primarily due to product mix. Consolidated gross margin increased to 57.3% from 56.9%.
- Operating income rose to $291.2 million from $67.5 million, and the company returned to net income. FY2019 included $229.5 million of goodwill and tradename impairment charges; FY2020 recorded none. FY2019 net loss also reflected the impairment and related tax effects.
- Operating cash flow increased $27.8 million, which management attributed primarily to higher income after non-cash items and lower working capital. Investing cash flow was a $16.6 million use, versus $55.4 million provided in FY2019, which included divestiture proceeds.
- Debt declined by $68 million. The company issued $400 million of 5.125% notes due 2028 and used the proceeds, together with cash, to redeem $400 million of 5.375% notes due 2021. It also made $48 million of voluntary term-loan repayments and repurchased $56.7 million of stock under its repurchase program.
Outlook, commentary, risks and unusual items
- COVID-19: The company reported increased orders and sales near the end of March 2020, followed by a significant decrease in consumer consumption in the weeks afterward. It had not experienced a material overall supply-chain disruption by the filing date, but cited substantial uncertainty around future demand, supply, distribution, workforce availability, costs, liquidity and operations. No quantified earnings or revenue guidance was provided.
- Debt and interest rates: The company was in compliance with debt covenants at year-end and management anticipated compliance during FY2021. Actual covenant ratios were not stated in the supplied filing text. Approximately $345 million of debt bore variable interest rates after hedging; a one-percentage-point increase was estimated to reduce pretax income and cash flows by about $3.7 million.
- Asset concentration and impairment: Goodwill and intangible assets totaled $3.055 billion, a substantial portion of total assets. Annual FY2020 testing found no impairment, with tested reporting-unit and indefinite-lived asset fair values at least 10% above carrying values. PwC identified impairment valuation as a critical audit matter because of the judgment involved in forecasts, margins and discount rates. FY2019 impairments included $33.5 million of goodwill and $195.9 million of intangible assets.
- Operations and customer concentration: U.S. distribution relies on one primary third-party distribution center; one Lynchburg facility produces products representing approximately 15% of gross sales. The company used 113 third-party manufacturers, while 14 manufacturers under long-term contracts supplied products representing 62.3% of gross sales. Walmart accounted for 23.1% of gross revenue and 20.2% of year-end receivables.
- Other items: FY2020 included a $2.2 million loss on extinguishment of debt and $9.2 million of cost-of-sales charges related to warehouse transition and acquisition/divestiture-related costs. The CARES Act’s interest-deduction change reduced FY2020 taxable income. The company stated it had no current intention to pay common-stock dividends.
- PwC gave unqualified opinions on the financial statements and internal control over financial reporting; management also concluded internal controls were effective as of March 31, 2020. Routine legal matters were not expected to have a material adverse effect, taking reserves into account.
Important facts for investors to verify
- How post-March 2020 consumer demand evolved after the reported pantry-loading surge and subsequent consumption decline, and the resulting effect on sales, inventory and cash conversion.
- Whether North American OTC margins recover from warehouse-transition costs and whether the International segment can sustain its revenue and margin gains.
- Debt reduction, interest expense, variable-rate exposure, covenant headroom and the availability of the ABL facility under changing operating conditions.
- The assumptions supporting the $3.055 billion carrying value of goodwill and intangible assets, particularly brand forecasts, discount rates and the potential effects of COVID-19.
- Customer and supply-chain concentration, including Walmart dependence, reliance on the primary distribution center and manufacturers without long-term contracts.
- The filing’s FY2020 adjusted performance, if used for valuation: GAAP results include identified transition and debt-extinguishment costs, while the prior-year comparison includes substantial impairment charges.